Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Inclusion Criteria: * Patients must be at least 18 years of age * HIV uninfected on the basis of a negative HIV rapid test, EIA or Western blot, and without any signs or symptoms of acute HIV infection * Able to understand and provide consent * High-Risk Exposure Characteristic (One or more of the below, unprotected or with failed condom use): * Receptive Anal Intercourse * Insertive Anal Intercourse * Receptive Vaginal Intercourse * Insertive Vaginal Intercourse * Receptive Oral Intercourse with Intraoral Ejaculation with known HIV+ source * High-Risk Source (One or more of the below): * Known HIV positive * MSM * MSM/W * CSW * Sexual perpetrator Partner of one of the above * Exposure within 72 hours of presentation * Not known to be HIV-1 positive * No countermanding concomitant medications or allergies Exclusion Criteria: * Patients \<18 years of age * Unable to understand and provide consent * Non-occupational exposure to HIV-1 not recent enough to commence the first dose of study medication within 72 hours from the exposure * Known to be HIV positive * Any condition which in the opinion of the intake provider will seriously compromise the patient's ability to comply with the protocol, including adherence to nPEP medication * Demonstrated HIV-1 positive on rapid testing * Unwillingness to commit to barrier-method (male and/or female condom) use until HIV negative status is confirmed 6 months after exposure * Unwillingness of breast-feeding women to transition to formula feeding * Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures * Pregnancy * Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive serum HBV DNA; or prior lamivudine or other therapy for hepatitis B * Creatinine clearance less than 30 mL/min as calculated by Cockcroft-Gault formula * Unwillingness to participate in study procedures, including Mental Health referral and intervention * Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir * Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which cannot be used with raltegravir